Kailera Therapeutics (KLRA) Jefferies Global Healthcare Conference 2026 summary

Vision and strategy

• Focused on delivering category-leading obesity management medications to empower health restoration, with an obesity-first approach and a comprehensive pipeline targeting diverse patient needs.

• Collaboration with Hengrui provides access to robust clinical datasets, accelerates development, and enables strategic, risk-adjusted capital allocation.

• Pipeline includes two injectables and two orals, aiming to address patients with both high and lower BMIs, supporting a tailored approach to obesity care.

• Ribupatide franchise includes both injectable and oral formulations, enabling flexible patient management and commercial synergies.

Clinical development and pipeline

• Lead asset ribupatide, a once-weekly GLP-1/GIP dual agonist, is in global phase III trials, showing mean weight loss of 23.6% at 8 mg over 36 weeks.

• Oral ribupatide demonstrated 12.1% weight loss at 25 mg over 26 weeks with a differentiated tolerability profile; phase III planned for 2027.

• KAI-7535, a once-daily oral small molecule GLP-1 agonist, entered global phase II in 2024; KAI-4729 (triple G) showed up to 16% weight loss in phase I and will enter global studies in 2024.

• Key data readouts expected: high-dose ribupatide phase II in 2027, oral ribupatide phase III start in 2027, KAI-7535 phase II data in 2027, and KaiNETIC phase III topline in 2028.

Clinical trial design and differentiation

• KaiNETIC 1 and 2 are FDA-mandated, placebo-controlled global phase III studies for obesity and type 2 diabetes, informed by Hengrui's phase II data.

• KaiNETIC 3 targets patients with BMI above 35, addresses unmet needs, explores higher doses, and includes a head-to-head comparison with semaglutide.

• High-dose ribupatide trial (up to 20 mg) aims to define maximum tolerated dose and inform future label and commercial strategies.

• Data-driven approach to future head-to-head studies against competitors like tirzepatide and retatrutide.